Form 4: Arvinas Director Linda Bain Reports Stock Option Grant and RSU Acquisition

Director Linda Bain reports the acquisition of stock options and restricted stock units (RSUs) in Arvinas, Inc.

Summary

• Linda Bain, a director of Arvinas, Inc., filed a Form 4 on May 31, 2024, reporting transactions related to the company's stock.
• On May 29, 2024, Bain acquired 5,899 shares of common stock through restricted stock units (RSUs) and disposed of 10,020 shares.
• Additionally, Bain was granted an option to purchase 9,070 shares of common stock at an exercise price of $33.90, exercisable starting May 29, 2025, and expiring on May 28, 2034.
• Following these transactions, Bain directly owns 9,070 derivative securities and 10,020 shares of Arvinas common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing of insider transactions. The acquisition of RSUs and stock options is generally positive, but the disposal of shares introduces a slightly negative element.

Positives

• The grant of stock options and RSUs to a director aligns their interests with those of the shareholders.
• The vesting schedule of the options and RSUs encourages long-term commitment from the director.

Negatives

• The disposal of 10,020 shares by the director could be interpreted negatively by some investors, although the acquisition of RSUs offsets this to some extent.

Risks

• The value of the stock options is dependent on the future performance of Arvinas, Inc.
• Market conditions and company-specific factors could impact the value of the underlying common stock.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates activity by a director, which is typical for publicly traded companies.

Comparison to Industry Standards

• Stock option grants and RSU awards are common compensation practices for directors in publicly traded companies, particularly in the biotechnology sector.
• Companies like Amgen, Gilead Sciences, and Biogen often use similar equity-based compensation to align director and shareholder interests.
• The vesting schedules and exercise prices are generally in line with industry standards for executive compensation.

Stakeholder Impact

• Shareholders may view the equity grants as a positive sign of aligning director interests with company performance.
• Employees may see the director's equity stake as a sign of confidence in the company's future.

Key Dates